The Development of Oral Nalbuphine Dosage Form

Not Applicable

• Conditions: Healthy
• Interventions: Drug: nalbuphine

• Registration Number: NCT00924079
• Lead Sponsor: Tri-Service General Hospital

Brief Summary

The purpose of this study is to investigate possible responses to pharmacokinetic properties for nalbuphine oral formulations in healthy volunteers.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-09
• Status Verified: 2009-06
• Study First Submitted: 2009-06-17
• Study First Submitted QC: 2009-06-17
• Study First Posted: 2009-06-18
• Last Update Submitted: 2009-06-18
• Last Update Posted: 2009-06-19
• Primary Completion: 2009-11

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Normal healthy adult subjects between 20-40 years of age.

• Body weight within 80-120% of ideal body weight. Ideal body weight = (height-80)0.7

• Acceptable medical history and physical examination including:

  • Normal chest X-ray and ECG results within six months prior to Period I dosing.
  • No particular clinical significance in general disease history within two months prior to Period I dosing.

• Acceptable clinical laboratory determinations without significant deviation from normal values within two months prior to Period I dosing, which includes:

  • AST (SGOT)
  • ALT (SGPT)
  • Gama-GT
  • alkaline phosphatase
  • total bilirubin
  • albumin
  • glucose
  • BUN
  • uric acid
  • creatinine
  • total cholesterol
  • triglyceride(TG)

• Acceptable hematology within two months prior to the study, which includes hemoglobin, hematocrit, red blood cells, MCV, MCH, MCHC, white blood cells, differential white blood cells and platelets.

• Acceptable urinalysis within two months prior to the study, which includes pH, blood, glucose and protein.

• Signed the written informed consent to participate in this study.

Exclusion Criteria

• Recent history of drug or alcohol addiction or abuse.
• A clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine or neurologic system(s) or psychiatric disease (as determined by the clinical investigator).
• History of allergic response(s) to nalbuphine or related drugs.
• History of clinically significant allergies including drug allergies or allergic bronchial asthma.
• Evidence of chronic or acute infectious diseases.
• Any clinically significant illness or surgery during the four weeks prior to Period I dosing (as determined by the clinical investigator).
• Taking any drug known to induce or inhibit hepatic drug metabolism within one month prior to the beginning of the study.
• Receiving any investigational drug within one month prior to Period I dosing.
• Taking any prescription medication or any nonprescription medication within two weeks prior to Period I doing.
• Donating greater than 150 ml of blood within two months prior to Period I dosing or donating plasma (e.g., plasmapheresis) within 14 days prior to Period I dosing. All subjects will be advised not to donate blood for four weeks after completing the study.
• Consumption of caffeine, xanthine-containing products (i.e., coffee, tea, caffeine-containing sodas, colas and chocolate, etc.) and/or alcohol at least 48 hours prior to days on which dosing is scheduled and during the periods when blood samples are being collected.
• Any other medical reason as determined by the clinical investigator.
• Patient is pregnant or breastfeeding. Women of childbearing potential must have a negative urine pregnancy test at Baseline.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
nalbuphine	nalbuphine	-

Primary Outcome Measures

Name	Time	Method
Pharmacokinetic parameter eq Cmax, AUC, Cl, T1/2	24 hours

Trial Locations

Locations (1)

Tri-Service General Hospitial; 🇨🇳 Taipei, Taiwan